• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, November 14, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

New method identifies splicing biomarkers for liver cancer

Bioengineer by Bioengineer
March 4, 2018
in Biology
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: Krainer Lab, CSHL

Cold Spring Harbor, NY – Because liver cancer is particularly diverse, genetically, and prone to relapse, identifying biomarkers that can predict disease progression is a critical goal in the fight against it.

Researchers at Cold Spring Harbor Laboratory (CSHL), led by CSHL Professor Adrian Krainer, now report in Genome Research that they have developed a method for identifying splicing-based biomarkers for the most common form of liver cancer, hepatocellular carcinoma (HCC). They believe the method will be useful in other cancer types as well.

"This study underscores the potential for learning how RNA splicing variants can contribute to cancer and points to these variants as potential biomarkers for cancer progression," Krainer says.

Splicing refers to a process in which an RNA message copied from information encoded in a gene is edited before it is able to serve as a blueprint for the manufacture of a specific protein. A gene can give rise to multiple RNA messages, each resulting in a different protein variant, or "isoform." Many diseases have been associated with errors or variations in the way that RNA is spliced. Errors or variations in splicing can lead to non-functional proteins or proteins with distinct or aberrant functions.

Recent studies have identified splicing irregularities in liver cancer cells. Led by CSHL postdoctoral researcher Kuan-Ting Lin, Krainer's team developed a method that comprehensively analyzes all RNA messages made from a given gene. The team tested their splicing-variant detection method in HCC, by analyzing RNA messages in HCC cells sampled from hundreds of patients.

They found that particular splicing isoforms of the gene AFMID correlated with very poor patient survival. These variants lead cells to manufacture truncated versions of the AFMID protein. These unusual versions of the protein are associated in adult liver cancer cells with mutations in tumor-suppressor genes called TP53 and ARID1A.

These mutations, the researchers hypothesize, are associated with low levels of a molecule called NAD+ that is involved in repairing damaged DNA. Restoring missing portions, called exons, to AFMID's normal RNA message, they propose, might raise NAD+ to normal levels, avoiding mutations in TP53 and ARID1A. The team hopes to use small molecules called ASOs (antisense oligonucleotides) that can bind to RNA, to change the way AFMID's RNA messages are spliced. Krainer's team previously used this technique to correct errors in the splicing of the gene SMN2 as a way to treat spinal muscular atrophy (SMA).

Fixing AFMID splicing could lead to enhanced production of NAD+ and an increase in DNA repair. "If we can do this, AFMID splicing can become a therapeutic target and the source of a new drug for liver cancer," Lin says. Preliminary experiments suggest the team is on the right track. They demonstrated that coaxing cells to over-express AFMID spliced in the normal manner led to higher NAD+ levels and slower growth of liver cancer cells.

###

Funding:

National Institutes of Health

Citation:

Lin, K-T et al, "A human-specific switch of alternatively spliced AFMID isoforms contributes to TP53 mutations and tumor recurrence in hepatocellular carcinoma," appears in the March 2018 issue of Genome Research.

About Cold Spring Harbor Laboratory

Founded in 1890, Cold Spring Harbor Laboratory has shaped contemporary biomedical research and education with programs in cancer, neuroscience, plant biology and quantitative biology. Home to eight Nobel Prize winners, the private, not-for-profit Laboratory employs 1,100 people including 600 scientists, students and technicians. The Meetings & Courses Program annually hosts more than 12,000 scientists. The Laboratory's education arm also includes an academic publishing house, a graduate school and the DNA Learning Center with programs for middle and high school students and teachers. For more information, visit http://www.cshl.edu

Media Contact

Peter Tarr
[email protected]
516-367-5055
@cshl

Cold Spring Harbor Laboratory – Advancing the frontiers of biology through education and research

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Sargassum’s Health Under Ocean Acidification and Nitrogen Boost

November 14, 2025
blank

New Microfluidic ‘MISO’ Platform Achieves High-Resolution Cryo-EM Using Minimal Starting Material

November 14, 2025

Targeting the Hippo Signaling Pathway: A New Therapeutic Approach for Nephronophthisis

November 14, 2025

Duplication and Mutation of Aquaporin Genes Restore Wide Solute Permeability in European Eels

November 14, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    318 shares
    Share 127 Tweet 80
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    210 shares
    Share 84 Tweet 53
  • New Research Unveils the Pathway for CEOs to Achieve Social Media Stardom

    200 shares
    Share 80 Tweet 50
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    141 shares
    Share 56 Tweet 35

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Understanding Huntington’s Disease: Expansion, Pathology, and Treatments

Impact of Nanosecond Electric Pulses on Mitochondria

Impact of Daily Activity on LVAD Patients’ Lives

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 69 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.